Innovation
Innovation
Improving Health for All
We develop new ways to promote faster development of valuable treatments and ensure diverse patient groups can access them.
Featured White Paper
The Elasticity of Pharmaceutical Innovation: How Much Does Revenue Drive New Drug Development?
For every 10% reduction in expected revenues, we can expect 2.5% to 15% less pharmaceutical innovation. Policymakers should take care to balance reductions in health outcomes long-term with short-term access improvements.
Experts: Karen Van Nuys, Darius Lakdawalla, Dana Goldman
Related Subtopics
High drug prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. We connect industry, academia and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Top Innovation Stories View All
Perspective
The Biotech Industry Needs to Make Its Case for Bold Change to the White House
Featured Experts: Joseph Grogan
In The News View All
POLITICO
“Most Favored Nation” could incentivize drugmakers to pull products overseas, hurting patients worldwide, Lakdawalla warns
Featured Experts: Darius Lakdawalla
ABC7
Pharmaceutical tariffs may raise prices and reduce innovation, explains Padula
Featured Experts: William Padula
ABC News
Padula says pharmaceutical tariffs could hit R&D budgets
Featured Experts: William Padula
Law360
Lawmakers shouldn’t overlook value of rare disease therapies, Chen argues
Featured Experts: Alice Chen
NPR
Goldman quoted on NIH nominee’s qualifications to promote science for the public good
Featured Experts: Dana Goldman
Team View All Innovation Experts
